Donepezil helps dementia by boosting levels of a brain chemical called acetylcholine, which is essential for memory, learning, and attention. It does this by blocking the enzyme that normally breaks acetylcholine down after nerve cells use it. The result is more acetylcholine available in the brain at any given moment, partially compensating for the nerve cell damage that Alzheimer’s disease causes. It is the most widely prescribed medication for Alzheimer’s and is approved for mild, moderate, and severe stages of the disease.
What Happens in the Brain
In a healthy brain, nerve cells communicate by releasing acetylcholine into the tiny gap between neurons. Once the message is delivered, an enzyme called acetylcholinesterase quickly breaks acetylcholine down into inactive fragments so the signal doesn’t keep firing. This cycle happens constantly and keeps thinking, memory, and attention running smoothly.
Alzheimer’s disease damages and destroys the nerve cells that produce acetylcholine. As those cells die off, the brain has less and less of this chemical messenger to work with, which is a major reason memory and reasoning decline. Donepezil works by attaching itself to acetylcholinesterase and temporarily disabling it. With less of the enzyme active, whatever acetylcholine the remaining nerve cells produce lingers longer in the gap between neurons, strengthening the signal. Research published in ACS journals confirms that donepezil physically occupies the same spot on the enzyme where acetylcholine would normally be broken down, essentially blocking the enzyme from doing its job.
This is a reversible process. Donepezil doesn’t permanently alter the enzyme; it holds on for a while, then releases. That’s why it needs to be taken daily to maintain the effect.
What Donepezil Can and Cannot Do
Donepezil is a symptomatic treatment. It does not slow, stop, or reverse the underlying brain cell destruction that drives Alzheimer’s disease. The plaques and tangles that characterize Alzheimer’s continue to accumulate regardless of whether someone is taking the medication. What donepezil does is make better use of the brain’s remaining resources, squeezing more function out of nerve cells that are still alive.
In practical terms, this means donepezil can temporarily stabilize or modestly improve symptoms like memory loss, confusion, and difficulty with everyday tasks. Over time, as the disease continues to destroy more neurons, the medication has fewer functioning cells to work with and its benefits gradually diminish. Even so, many patients and families notice a meaningful difference in day-to-day function while the drug is working, and it remains a mainstay of Alzheimer’s treatment.
How Much Improvement to Expect
Clinical trials consistently show a modest but measurable cognitive benefit. On the ADAS-Cog, a 70-point scale commonly used to track thinking ability in Alzheimer’s research, people taking donepezil score about 2.5 to 3.5 points better than those on placebo after six months. A World Health Organization review of 21 randomized trials involving over 3,200 participants found an average improvement of about 3.3 points, which meets the threshold researchers consider a minimally clinically important difference.
What does that look like in real life? It varies. For some people, it means remembering a grandchild’s name more reliably, following a conversation with less confusion, or managing a familiar daily routine with less help. For others, the benefit is less noticeable. The improvement tends to be most apparent in the first six to twelve months. After that, cognition typically begins declining again, though often more slowly than it would without treatment. Some people stay on donepezil for years because stopping it can lead to a noticeable and sometimes rapid drop in function.
Common Side Effects
Because donepezil increases acetylcholine throughout the body (not just in the brain), its most common side effects involve the digestive and nervous systems. In clinical trials of the standard dose, about 11% of people experienced nausea compared to 6% on placebo, and about 10% had diarrhea compared to 5% on placebo. Insomnia affected roughly 9% of people taking the drug versus 6% on placebo.
These side effects are dose-dependent. When people were moved to a higher dose too quickly (over one week instead of six), nausea rates jumped to 19% and diarrhea to 15%. A slower, more gradual increase in dose significantly reduces these problems. Most gastrointestinal side effects are mild and tend to fade within the first few weeks as the body adjusts.
Heart-Related Considerations
Acetylcholine also influences heart rhythm. Donepezil can slow the heart rate and affect the electrical signals that coordinate heartbeats. In some cases, this leads to fainting, unusually slow heart rate, or a type of irregular rhythm called heart block. These effects are uncommon but more of a concern for people who already have heart conduction problems or who take medications like beta-blockers that also slow the heart. New fainting episodes in someone taking donepezil should be evaluated promptly, as the combination of the drug with other heart-slowing medications can amplify the effect.
How It Compares to Other Options
Donepezil belongs to a class of drugs called cholinesterase inhibitors. Two other medications in this class, rivastigmine and galantamine, work through the same basic mechanism and produce similar levels of cognitive benefit. The main differences between them are practical: how often they’re taken, whether they come as a patch or pill, their side effect profiles, and their cost. Guidelines from NICE recommend starting with whichever cholinesterase inhibitor has the lowest cost, then switching to an alternative if side effects are a problem or the medication isn’t well tolerated.
For moderate to severe Alzheimer’s, donepezil is sometimes combined with memantine, a medication that works through a completely different brain signaling system. Donepezil is the only cholinesterase inhibitor approved across all three stages of Alzheimer’s (mild, moderate, and severe), which gives it a practical advantage as the disease progresses. The other two are typically used for mild to moderate stages only.
What Taking It Looks Like
People typically start at a low dose taken once daily, usually in the evening. After four to six weeks, if the medication is tolerated well, the dose is increased. This gradual approach gives the body time to adjust and significantly reduces the chance of stomach-related side effects. For people with moderate to severe Alzheimer’s who have been on the standard dose for at least three months, a higher-dose tablet is available, though it comes with a greater likelihood of nausea (12% versus 3% at the standard dose).
Donepezil is taken as a tablet or an orally disintegrating tablet that dissolves on the tongue, which can be helpful for people who have trouble swallowing pills. It’s taken once a day, which is simpler than some alternatives that require twice-daily dosing or patch application. Effects on cognition and daily function are typically assessed after a few months, and the decision to continue depends on whether the person and their family notice a benefit and whether side effects are manageable.